Jasper Therapeutics receives Nasdaq notice over stockholders' equity shortfall

Jasper Therapeutics disclosed in an 8-K that on August 21, 2026, it received a letter from Nasdaq stating that, based on stockholders' equity reported in its Form 10-Q for the period ended June 30, 2026, the company fell below the $2,500,000 minimum equity threshold required to keep its listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1).¹

The notice does not immediately affect the company's listing or trading status, as long as it continues to meet Nasdaq's other listing requirements.¹ Under Nasdaq Marketplace Rule 5810(c)(2)(C), Jasper has a 45-day window, running to October 5, 2026, to file a compliance plan explaining how it will address the equity shortfall.¹

The company said it expects to resolve the deficiency once shareholders approve converting its outstanding Non-Voting Convertible Preferred Stock into common shares, a vote it plans to hold at a forthcoming special stockholder meeting, though it cautioned that there is no guarantee the required approvals will be obtained or that compliance will ultimately be achieved.¹

If Nasdaq accepts the compliance plan, Jasper could receive up to 180 additional calendar days from August 21, 2026 to regain compliance.¹ Should the plan be rejected, or accepted but not fulfilled within that extended window, Jasper would be entitled to request a hearing before Nasdaq's Hearing Panel, and that request would pause any delisting or suspension action while the hearing process plays out.¹ The company noted there is no assurance the panel would grant continued listing or that compliance could ultimately be maintained.¹